Antiviral Discovery for Highly Pathogenic Emerging Viruses

個数:

Antiviral Discovery for Highly Pathogenic Emerging Viruses

  • 在庫がございません。海外の書籍取次会社を通じて出版社等からお取り寄せいたします。
    通常6~9週間ほどで発送の見込みですが、商品によってはさらに時間がかかることもございます。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合がございます。
    2. 複数冊ご注文の場合、分割発送となる場合がございます。
    3. 美品のご指定は承りかねます。

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Hardcover:ハードカバー版/ページ数 308 p.
  • 言語 ENG
  • 商品コード 9781788015646
  • DDC分類 615.7924

Full Description

New antiviral drugs are urgently needed. Recent outbreaks caused by viruses with great epidemiological impact such as Zika, or extraordinary virulence such as Ebola, Nipah, Lassa, Crimean-Congo haemorrhagic fever highlight the current lack of clinically proven vaccines and treatments for these potentially catastrophic agents. Antiviral Discovery for Highly Pathogenic Emerging Viruses comprehensively outlines the state of the art in antiviral drug discovery including identification of targets, screening strategies and the current pipeline of antiviral candidates including regulatory issues. The book also addresses the challenges faced in proceeding from pre-clinical studies to animal models and clinical trials with these highly pathogenic agents.

Ideal for drug discovery scientists and medicinal chemists with an interest in antiviral drug discovery and development, this book provides a complete overview of the latest progress in the field, recent advances and the challenges that remain in developing these highly pathogenic agents. Illustrated throughout with case studies this book is a valuable resource in this complex and multidisciplinary field.

Contents

Overview of Antiviral Drug Discovery and Development: Viral Versus Host Targets;

Advances in Prophylaxis and Therapy of Arenavirus Hemorrhagic Fevers;

Vaccines and Antiviral Developments for SARS-CoV-2 in the Emergence of the COVID-19 Pandemic;

Small-molecule and Synthetically Derived Antivirals for Ebola Virus and Other Filoviruses;

Antiviral Strategies for Ebola Virus and Other Filoviruses: Antibodies;

Vaccine Development in the Midst of Ebolavirus Disease Outbreaks;

Remdesivir: Investigational Antiviral Drug with Activity Against Ebola and Other Emerging and Neglected Viruses;

Therapeutics Against Nipah and Hendra Virus;

Glycomimetics as Promising Inhibitors of Ebola Virus, Flavivirus and HIV Infections;

Repurposing Approved Drugs to Block Highly Pathogenic Emerging Viruses;

Receptors on Primary Phagocytes as Therapeutic Targets Against Highly Pathogenic Emerging Viruses

最近チェックした商品